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5. Extra column volume
Outline
1. Introduction
Use of fused-core and sub-












no peak area mass balance in stability samples
Approach: RF determination degradants by dry heat stress of
β-artemether under different environments
Protocol
Ref.: De Spiegeleer, D’Hondt et al.  Journal of Pharmaceutical and biomedical Analysis 70 (2012) 111-116




Temp (°C) 125 125 130 130 130 140 140 145 145
Time (min) 30 60 30 60 90 15 45 15 30
Oxidative
Temp (°C) 125 125 130 130 130 140 140 145 145
Time (min) 30 60 15 45 90 15 45 15 30
Neutral
Temp (°C) 130 130 140 140 140 145 145 150 150
Time (min) 30 60 15 30 60 15 30 10 20
+ blanks, refs.                            Approx. 50 samples
Need for fast, efficient separation chromatography
Method transfer: traditional HPLC method vs. new UPLC method (β-artemether 140°C, 15 min.)
Ref.: De Spiegeleer, D’Hondt et al.  Journal of Pharmaceutical and biomedical Analysis 70 (2012) 111-116
2.    Small molecules
Artemether (1/2)
UPLC BEH Shield RP 18 (100 × 2.1 mm I.D., 1.7 m particle size)
Waters Acquity UPLC H-Class
Prevail Organic Acid  (250 × 4.6 mm I.D., 5 µm particle size)
Waters 2695 separations module
Total run time: 85 min
±71 hrs / 50 samples
Total run time: 17.5 min





Concl.: RRF up to 42
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Ref.: Suleman, Vandercruyssen, Wynendaele, D’Hondt et al. Manuscript in preparation




Controlled distribution and storage                         African setting
Need: Fast stability-indicating simultaneous assay of lumefantrine and β-artemether   
Lumefantrine
Ref.: Suleman, Vandercruyssen, Wynendaele, D’Hondt et al. Manuscript in preparation




















•Column: HALO RP-amide (50 × 4.6 mm 
I.D., 2.7 µm particle size)
•Mobile phase:
Acetonitrile / 1 mM phosphate buffer pH 
3.0 (52:48, V/V)
•Flow rate: 1.0 ml/min 
•Detection: 210 nm (β-artemether) and 
335 nm (lumefantrine)
•Column temperature: 30oC
•Injection volume: 3 µl














Concl.: ideal, esp. for resource limited countries
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Ref.: D’Hondt et al. American Journal of Health-System Pharmacy 69 (2012) 232-240
2.    Small molecules
Triple IT
Triple IT solution:
Treatment of acute lymfoblastic leukemia                 in-situ prepared before each! administration
In-use stability protocol:
• 3 different batches
• 3 different packaging materials
• 3 different storage conditions
• Time points (n=6): 0, 4, 8, 24, 32, 48 hrs.
Cytarabine Methotrexate Methylprednisolone (21) sodium succinate
#Samples 
need for fast! simultaneous
stability-indicating assay method
Ref.: D’Hondt et al. American Journal of Health-System Pharmacy 69 (2012) 232-240
2.    Small molecules
Triple IT
Method:
•Column: Halo C18 (150 × 4.6 mm I.D.; 
2.7 µm particle size)
•Mobile phase:
A: 0.1% V/V glacial acetic acid in H2O
B: 0.1% V/V glacial acetic acid in ACN
•Gradient:
0  15 min: 90  10% A
•Flow rate: 1 ml/min
•Column temperature: 30oC
•Injection volume: 10 µl
•Detection: 240 nm (MPSS) and
280 nm (CB and MT)
240 nm
280 nm






















Fit for in-use stability protocol
Concl.: stable for 12 hrs at 5°C
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Ref.: D’Hondt et al. Manuscript in preparation




• Kinetic degradation profile of buserelin
• Degradation profile for MS identification
Stability protocol
• 5 temperature settings
• 4 time points / temperature
• Duplicate
• + refs, blanks
Approx. 60 samples
Need for fast stability-indicating assay method
Ref.: D’Hondt et al. Manuscript in preparation
3.   Peptides
Buserelin
Method:
•Column: Acquity UPLC BEH 300 RP 18
(100 × 2.1 mm I.D., 1.7 µm particle size)
•Mobile phase:
MP A: 95% water and 5% acetonitrile with 0.1% 
formic acid (m/V)
MP B: 95% acetonitrile and 5% water with 0.1% 
formic acid (m/V)
•Gradient:
0     1.5 min: 100% A
1.5  11 min: 100% A  79% A
11   18 min: 79% A
•Flow rate: 0.6 ml/min
•Column temperature: 30oC
•Injection volume: 2 µl
•Detection: 220 nm
•Total run time: 35 min
Method verification
•Linearity (1% to 100%): R² = 0.9966
•Repeatability (6x 100%): %RSD = 0.99
•LoD: 0.04% relative to 100% solution
Buserelin assay  kinetics and Ea
Separation and identification of degradants (MS)
Buserelin 165°C for 60 min
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Ref.: D’Hondt et al. Food Chemistry 128 (2011) 114-122
3.   Peptides
Peptide mixture
Method:
•Column: HALO Peptide ES-C18
(75× 3 mm I.D., 2.7 µm particle size)
•Mobile phase:
MP A: 0.1% formic acid (m/V) in H2O
MP B: 0.1% formic acid (m/V) in ACN
•Gradient:
0  40 min: 95% A 71% A
•Flow rate: 0.6 ml/min
•Column temperature: 30oC
•Injection volume: 10 µl
•Detection: 220 nm
•Total run time: 60 min
Pancreatic casein digest
(peaks indicated by number were identified by means of MS)





















In-silico AAdescriptor = – 0.692 + 4.131 AlogP + 1.330 Alog P2 - 17.517 Mor10v + 6.613 
Mor10e + 9.302 E1u + 0.240 RDF035e Name AlogP AlogP2 Mor10v Mor10e E1u RDF035e AA descriptor
Alanine -0,601 0,361 0,044 0,03 0,473 5,862 2,539767
Arginine -1,107 1,225 0,09 -0,06 0,572 10,992 2,349747
Asparagine -1,847 3,413 -0,051 -0,327 0,495 8,225 1,526739
Aspartic acid -1,245 1,55 -0,093 -0,251 0,545 4,121 2,254253
Cysteine -0,517 0,268 -0,031 -0,201 0,414 5,521 1,918595
Glutamic acid -0,924 0,854 -0,026 -0,244 0,538 6,312 1,988002
Glutamine -1,526 2,329 0,03 -0,035 0,565 7,961 2,510969
Glycine -0,978 0,957 0,009 0,111 0,518 0,096 1,958558
Histidine -1,015 1,031 0,029 -0,135 0,549 7,499 1,992075
Isoleucine 0,699 0,488 0,159 0,221 0,466 12,577 8,874091
Leucine 0,631 0,398 -0,05 -0,329 0,567 11,282 9,126088
Lysine -0,68 0,462 0,168 0,143 0,556 6,342 1,810175
Methionine -0,273 0,075 -0,012 0,034 0,519 5,179 4,785731
Phenylalanine 0,955 0,913 -0,062 -0,229 0,546 9,758 11,45988
Proline -0,057 0,003 0,439 0,887 0,51 1,613 2,383431
Serine -1,489 2,217 0,08 0,359 0,417 3,574 1,814952
Threonine -1,111 1,235 0,113 0,042 0,598 6,868 1,87025
Tryptophan 1,249 1,56 0,226 0,17 0,56 13,881 12,24835
Tyrosine 0,688 0,473 -0,05 -0,342 0,503 10,771 8,657368
Valine 0,242 0,059 0,096 -0,069 0,477 8,55 4,737297
Aba-Gly -0,414 0,172 0,126 -0,012 0,438 17,382 3,785984
Dmt -1,107 1,225 -0,022 -0,605 0,585 7,655 0,027612
D-Arginine 1,66 2,757 -0,036 -0,431 0,433 18,435 16,06485
D-Penicillamine 0,065 0,004 0,009 0,22 0,528 14,375 9,240498
D-Phenylalanine 0,955 0,913 -0,002 -0,463 0,541 11,978 9,347712
D-Tryptophan 1,249 1,56 0,126 -0,234 0,555 18,93 12,49365
Ornithine -1,136 1,29 0,098 -0,019 0,542 6,517 1,094335
Penicillamine 0,065 0,004 -0,033 -0,071 0,498 12,063 7,217889
PyroGlu -0,673 0,452 0,401 0,777 0,526 3,756 1,037273
4. BBB peptides
Fused-core modelling
































Exp. AA retention time (min)
Ref.: D’Hondt et al. Journal of Pharmaceutical Analysis, accepted for publication.                    
Classic AAdescriptor = AA RT 
Column MP R² F Constant Log Sum AA cLogP Log Sv Log nHDon Log nHAcc
Peptide
FA/ACN 0,83 9,772 -4,101 7,68 0,085 -2,276 -8,815 7,849
FA/MeOH 0,93 26,51 -6,252 12,169 0,124 -2,514 -10,761 8,951
HOAc/ACN 0,829 9,722 -4,096 9,275 0,1 -2,893 -9,787 8,522
HOAc/MeOH 0,937 29,912 -7,619 11,886 0,145 -1,761 -11,451 9,772
Amide
FA/ACN 0,839 10,391 -8,561 13,271 0,163 -4,062 -17,024 16,039
FA/MeOH 0,858 12,105 -12,25 29,046 0,267 -10,904 -28,922 26,048
HOAc/ACN 0,865 12,856 -6,303 17,462 0,163 -7,686 -19,942 18,493
HOAc/MeOH 0,866 12,95 -16,915 30,853 0,311 -11,525 -38,596 36,06
Phenyl
FA/ACN 0,799 7,965 -1,623 6,852 0,053 -2,688 -5,147 4,071
FA/MeOH 0,916 21,806 -4,817 13,688 0,112 -4,359 -10,683 8,703
HOAc/ACN 0,808 8,395 -3,524 9,471 0,099 -3,298 -9,784 8,419
HOAc/MeOH 0,924 24,234 -6,146 13,229 0,126 -3,083 -11,401 9,122
C18
FA/ACN 0,861 12,376 -8,808 12,671 0,146 -3,544 -17,102 16,136
FA/MeOH 0,908 19,728 -13,617 27,362 0,242 -8,625 -30,391 27,159
HOAc/ACN 0,858 12,072 -7,577 17,145 0,151 -7,013 -21,259 19,811
HOAc/MeOH 0,915 21,517 -16,118 29,241 0,267 -9,966 -35,557 32,719
RTpeptide = b0 + b1 log ∑(AAdescriptor) + b2 cLogP + b3 log Sv + b4 log nHDon + b5 log nHAcc
4. BBB peptides
Fused-core modelling

























Exp. peptide RT (min)
HALO Peptide (FA/ ACN)
Buserelin
Includes unnatural AAs




(plant extract – cosmeceuticals)
Ref.: Boonen et al. Journal of Pharmaceutical Analysis, manuscript  submitted
Transdermal: several 100 FDC samples (low concentration  injection volume    )
Influence of injection volume on chromatographic responses (extra-column aspect):
Method:
•Column: HALO RP Amide
(50 × 4.6 mm I.D., 2.7 µm particle size)
•Mobile phase:
1% formic acid (m/V) in MeOH/H2O (70/30)
•Flow rate: 1.5 ml/min
•Column temperature: 30oC
•Detection: 237 nm
•Total run time: 2 min
•Injection volume: 2 to 100 µl
•Mass on column: constant
•Model compound: spilanthol
•Sample solvent: PBS

























Retention time Area Height Theoretical plates Symmetry factor
.
Thank you for your attention!
